{
  "ticker": "PYC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970878",
  "id": "02970878",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250721",
  "time": "0842",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250721/pdf/06lz6y79ply9b4.pdf",
  "summary": "### **Material Information Summary**  \n\n#### **Quarterly Report (Appendix 4C)**  \n- **Cash balance (30 June 2025):** **$153.0 million** (includes expected $20m R&D rebate in H2).  \n- **Q2 cash burn (operating activities):** **($17.7 million)**.  \n- **Financing (Q2):** Net $32.9 million from financing (follow-on from prior $146m capital raising).  \n- **Key milestones achieved:**  \n  - **PKD:** Completed dosing in Cohorts 1 & 2 of Phase 1a/1b trial.  \n  - **RP11 (blinding eye disease):** FDA alignment on registrational trial framework; Phase 1/2 data showed vision improvement.  \n  - **ADOA (blinding eye disease):** Dosing completed in Cohort 2; escalation to Cohort 3 approved.  \n  - **PMS (neurodevelopmental disorder):** Preclinical data supports 2026 clinical trials.  \n- **H2 2025 catalysts:**  \n  - **PKD:** Initiate Phase 1a/1b Part B (patients) and repeat-dose studies.  \n  - **RP11:** FDA Type D meeting for registrational trial design.  \n  - **ADOA:** Phase 1/2 MAD study initiation and initial efficacy data.  \n  - **PMS:** GLP tox studies for IND submission.  \n\n#### **Capital Structure Update**  \n- **Runway:** Funding secured into CY2027 (>$200m post-rebate).  \n\n*No material non-operational or liquidity risks flagged.*  \n\n---  \n*Brevity rule applied: Excluded forward-looking disclaimers, pipeline descriptions, and non-material operational details.*",
  "usage": {
    "prompt_tokens": 6577,
    "completion_tokens": 373,
    "total_tokens": 6950,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-20T22:51:52.340842"
}